ABSTRACT
Introduction: SARS-CoV2 infecction has a high impact on lung transplant patients. Sotrovimab, an Ig1 monoclonal antibody, has been shown to be effective for the treatment of SARS-CoV2 infection, and could be an option for these patients. Aims and objectives: Describe the evolution of the patients who have received treatment with Sotrovimab. Method(s): Observational retrospective study, which included lung transplant patients who received Sotrovimab for SARS-CoV2 infection, at the Puerta de Hierro Hospital. The study period is from November 2021 to January 2022. Variables: age, sex, type of transplant, days from Active Infection Diagnostic Test (AIDT) until drug administration, admission unit - ward, Intermediate Respiratory Care Unit (IRCU) or Intensive Care Unit (ICU) and days of admission. Also need for respiratory support, complications and death. Result(s): A total of 13 patients (9 males) with a mean age of 61 years (+/-12.3) with doble-lung transplant in 10 of them. The mean time from the AIDT until recieve Sotrovimab was 6+/-3 days. All patients required hospitalization with a mean of stay 16+/-11 days. 5 patients were admitted to the IRCU and 1 patient to the ICU. 2 patients were still hospitalized at the time of data collection (1 in the IRCU and 1 in the ICU). All patients required respiratory support (table 1). The complications are described in table 1. 3 patients died. Conclusion(s): Sotrovimab is a therapeutic option in lung transplant patients with SARS-CoV2 infection.